The global antihyperlipidemic drugs market accounted for $9,456 million in 2018, and is expected to reach $16,864 million by 2026, registering a CAGR of 7.5% from 2019 to 2026. Lipids are defined as the organic compounds that are fatty acids. These fatty acids are essential and serve as building blocks of the cellular membranes in the living organisms. However, a surge in level of lipids in the blood leads to their deposition in the arteries. This deposition of the lipids in the arteries leads to blockage, which in turn increases the risk of heart attacks. Therefore, the condition requires early detection and treatment. The treatment of hyperlipidemia is carried out using antihyperlipidemic drugs. Some of the antihyperlipidemic drugs available in the market include statins, bile acid sequestrants, cholesterol absorption inhibitors, and others.
The factors that contribute for the growth of the market include a surge in sedentary lifestyle. Furthermore, rise in incidence of disorders related to distributed cholesterol levels in the blood also contributes to the growth of the antihyperlipidemic drugs market. Moreover, a surge in awareness regarding complications related with hyperlipidemia is another major factor that fuels the growth of the market. However, high cost of the treatment hinders the market growth. Conversely, growth opportunities exhibited by emerging economies is expected to offer lucrative opportunities for the market growth during the forecast period.
The antihyperlipidemic drugs market size is studied based on segments, drug class and region, to provide a detailed assessment of the market. Based on drug class, the market is divided into statins, pcsk9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and combination. Based on region, the antihyperlipidemic drugs market size is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
Key Market Segments
By Region
List of key players profiled in the report:
The antihyperlipidemic drugs market size is studied based on segments, drug class and region, to provide a detailed assessment of the market. Based on drug class, the market is divided into statins, pcsk9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and combination. Based on region, the antihyperlipidemic drugs market size is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis along with the current global antihyperlipidemic market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
- By Drug Class
- Statins
- PCSK9 Inhibitors
- Bile Acid Sequestrants
- Cholesterol Absorption Inhibitors
- Fibric Acid Derivatives
- Combination
- Symptoms Check
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
List of key players profiled in the report:
- Boehringer Ingelheim GmbH
- Merck KGaA
- Johnson and Johnson
- Bayer AG
- Pfizer, Inc.
- Takeda Pharmaceutical Co., Ltd.
- AstraZeneca plc,
Table of Contents
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Overview
Chapter 4: Antihyperlipidemic Drugs Market, By Drug Class
Chapter 5: Antihyperlipidemic Drugs Market, By Region
Chapter 6: Company Profiles
Executive Summary
According to the report titled, 'Antihyperlipidemic Drugs Market by Drug Class: Global Opportunity Analysis and Industry Forecast, 2019-2026', the global antihyperlipidemic drugs market was valued at $9,456 million in 2018, and is expected to reach $16,865 million by 2026, registering a CAGR of 7.5% from 2019 to 2026.The rise in level of lipids in the blood is called as hyperlipidemia. The drugs that are used to treat the condition are called antihyperlipidemic drugs. Furthermore, there are major complications associated with this condition such as heart attack. Therefore, the condition requires early monitoring and treatment. Some of the antihyperlipidemic drugs available in the market include statins, bile acid sequestrants, cholesterol, and others.
Sedentary lifestyle is a major factor that contributes to the growth of antihyperlipidemic drugs market. Moreover, a surge in incidence of disorders related to distributed cholesterol levels in the blood also contributes to the growth of the antihyperlipidemic drugs market. Moreover, a surge in awareness regarding complications related with hyperlipidemia is another major factor that fuels the growth of the market. However, high cost of the treatment is expected to hinder the market growth. Conversely, growth opportunities exhibited by emerging economies is anticipated to offer lucrative opportunities during the forecast period.
The antihyperlipidemic drugs market size is studied based on segments, drug class, and region to provide a detailed assessment of the market. Based on drug class, the market is divided into statins, PCSK9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and combination. Based on region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
According to drug class, statins occupied the largest antihyperlipidemic drugs market share in 2018, owing to a surge in the incidence of cardiovascular disorders. Furthermore, statins reduce the risk associated with heart attacks, which is another major factor that contributes to the growth of the market. Moreover, PCSK9 inhibitors segment is expected to register the fastest growth during the forecast period, owing to the benefits offered such as drastic reduction of LDL levels in the blood. The other factors that boost the growth of the market include the a surge in the geriatric population and rise in healthcare expenditure across the globe. In addition, the other factors which boost the growth of the market include the additional benefits offered by the statins such as improved endothelial function, enhance the stability of atherosclerotic plaques, and reduce the amount of inflammation & damage done to cells due to oxidative stress.
In 2018, North America accounted for the major share of antihyperlipidemic drugs market size, and is expected to remain dominant during the forecast period, owing to easy availability of the antihyperlipidemic drugs. Moreover, a surge in the sedentary lifestyle is another major factor that contributes to the growth of the market. Furthermore, a surge in the obese population is another major factor that fuels the growth of the antihyperlipidemic drugs market. In addition, the presence of major key players such as Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Merck & Co., Inc. and others is another major factor that fuels the growth of antihyperlipidemic drugs market in the region. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period, owing to a surge in awareness related to the use of antihyperlipidemic drugs.
The developing economies offer lucrative opportunities for antihyperlipidemic drugs providers to expand their business. The constantly evolving life science industry drives the growth of the market in the developing economies such as India, China, and others. Furthermore, this report entails a detailed quantitative analysis along with the current global antihyperlipidemic drugs market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
Key findings of the study:
Statins occupied one-third share of the global antihyperlipidemic drugs market in 2018.
The PCSK9 inhibitors segment is anticipated to grow with the highest CAGR throughout the forecast period.
The cholesterol absorption inhibitors segment accounted for more than one-fourth share of the market in 2018.
Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.
Companies Mentioned
- Boehringer Ingelheim GmbH
- Merck KGaA
- Johnson and Johnson
- Bayer AG
- Pfizer Inc. Takeda Pharmaceutical Co. Ltd.
- AstraZeneca plc
- Daiichi Sankyo Company
- Sanofi S.A.
- Novartis International AG.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
